J. Goldman & Co’s Epizyme, Inc EPZM Stock Holding History

J. Goldman & Co’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-36,000	Closed	-$391K	–	577
2020 Q4	$391K	Buy	+36,000	New	+$444K	0.02%	294

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

J. Goldman & Co's EPZM Position: Q4 2019 in Review

J. Goldman & Co sold out of Epizyme, Inc (EPZM) in Q4 2019, closing a stake of 370,454 shares — an estimated $3.82M sold.

J. Goldman & Co first reported a position in EPZM in Q3 2016 and held it in 3 quarters. The position peaked at $3.82M in Q3 2019. 136 funds tracked by Wall St. Rank hold EPZM as of Q4 2019.

J. Goldman & Co reported no remaining Epizyme, Inc position as of Q4 2019 after selling out during the quarter.
J. Goldman & Co sold 370,454 Epizyme, Inc shares in Q4 2019, an estimated $3.82M.
J. Goldman & Co first reported a position in Epizyme, Inc in Q3 2016 and held it in 3 quarters.
J. Goldman & Co's Epizyme, Inc position peaked at $3.82M in Q3 2019.
136 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2019.

Based on J. Goldman & Co's 13F filing for Q4 2019, filed 14 Feb 2020.